1,4-pyridone bicycic heteroaryl compounds

• US 10,150,759 B2
• Filed: 06/16/2017
• Issued: 12/11/2018
• Est. Priority Date: 12/21/2012
• Status: Active Grant

• Current Assignee: Epizyme, Inc. (Ipsen Sa)
• Original Assignee: Epizyme, Inc. (Ipsen Sa)
• Inventors: Kuntz, Kevin W., Campbell, John Emmerson
• Primary Examiner(s): Carcanague, Daniel R
• Application Number:
  US15/625,779
• Publication Number:
  US 20180134692A1
• Time in Patent Office: 543 Days
• Field of Search: 546300
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07D 401/12 linked by a chain containing hetero atoms as chain links
• CPC Class Codes: C07D 401/14 containing three or more hetero rings
• CPC Class Codes: C07D 405/14 containing three or more hetero rings
• CPC Class Codes: C07D 471/04 Ortho-condensed systems

Abstract

The present invention relates to 1,4-pyridone bicyclic heteroaryl compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.

Claims

1. A method of treating leukemia or melanoma, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (IV) or a pharmaceutically acceptable salt thereof:

6. The method of claim 1, wherein R₇ is sec-butyl, cyclopentyl, or iso-propyl.

7. The method of claim 1, wherein R₆ is

11. The method of claim 6, wherein R₆ is

14. The method of claim 1, wherein the compound is comprised in a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.

17. The method of claim 1, wherein the leukemia is chronic myelogenous leukemia (CML), acute myeloid leukemia, acute lymphocytic leukemia or mixed lineage leukemia, or myelodysplastic syndromes (MDS).

2. A method of treating leukemia or melanoma, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (V) or a pharmaceutically acceptable salt thereof:

18. The method of claim 2, wherein the leukemia is chronic myelogenous leukemia (CML), acute myeloid leukemia, acute lymphocytic leukemia or mixed lineage leukemia, or myelodysplastic syndromes (MDS).

3. A method of treating leukemia or melanoma, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (VI) or a pharmaceutically acceptable salt thereof:

4. The method of claim 3, wherein the compound is of Formula (VIc):

5. The method of claim 4, wherein R⁷⁰⁶ is sec-butyl, cyclopentyl, or iso-propyl.

8. The method of claim 3, wherein R₆ is

9. The method of claim 4, wherein R₆ is

10. The method of claim 5, wherein R₆ is

12. The method of claim 3, wherein R₇ is sec-butyl, cyclopentyl, or iso-propyl.

13. The method of claim 3, wherein the compound is Compound 1 or 2:

15. The method of claim 3, wherein the compound is comprised in a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.

16. The method of claim 13, wherein the compound is comprised in a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.

19. The method of claim 3, wherein the leukemia is chronic myelogenous leukemia (CML), acute myeloid leukemia, acute lymphocytic leukemia or mixed lineage leukemia, or myelodysplastic syndromes (MDS).

20. The method of claim 13, wherein the leukemia is chronic myelogenous leukemia (CML), acute myeloid leukemia, acute lymphocytic leukemia or mixed lineage leukemia, or myelodysplastic syndromes (MDS).